Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate

Bioavailability Study Clinical Trial

— BIODYMF  

Official title:

Open Label Two -Treatment Half Side Comparative Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasoen Propionate

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02883439
• Other study ID #: 2015-002865-40
• Status: Withdrawn
• Phase: N/A
• Start date: August 2016
• Est. completion date: March 2020

Study information

• Verified date: July 2021
• Source: University Hospital, Ghent
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to investigate and to compare the bioavailability of MP29-02 and fluticasone propionate in nasal tissue after nasal application. This may provide a rational basis for the use of 1 puff per nostril dosage regimen of the drugs. Clinical experience has demonstrated the efficacy of the twice-daily treatment; however, so far, no data are available on the local tissue concentrations of MP29-02 after topical application.

Description:

The study will be a single-centre, two-treatment half-side comparative open-label trial; all subjects will receive Dymista® or Flixonase Aqua in one nostril each.

Nasal tissue samples will be obtained from 24 patients. Subjects will be selected based on the subjects plan to undergo septoplasty, septorhinoplasty, or functional endoscopic sinus surgery. Subjects with different diagnoses can be added in the study: non-allergic rhinitis, allergic rhinits, chronic sinusitis and nasal polyposis. The number of subjects is based on a previous experiment where the presence of fluticasone propionate was tested on human nasal mucosal surface and in human nasal tissue after nasal application (Bonsmann, 2001).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 2020
• Est. primary completion date: March 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• - Male and female patients

• Age: 18 - 70 years (included)

• Subjects who need to undergo septoplasty, septorhinoplasty or functional endoscopic sinus surgery unrelated to this study

• Willing and able to provide informed consent

Exclusion Criteria:

• - Patients who are member of the staff or relatives thereof directly involved in the conduct of the protocol

• Participant in any other trial during the last 30 days

• Previous treatment with Dymista or any other topical corticosteroid spray or drops within the last month before the operation

• Previous treatment with systemic corticosteroid in the last 2 months before operation

• Previous treatment with anti-histaminics 7 days before operation

• Pregnant or breast feeding women

• Allergic for one of the compounds azelastinehydrochloride or fluticasonpropionate

• Significant co-morbidity (for instance, but not limited to):

• Glaucoma, cataracts, and increased intraocular pressure.

• Subjects with active or quiescent tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex

• Subjects with severe liver disease

• Use of prohibited concomitant medication

• Potent inhibitors of cytochrome P450 (CYP) 3A4

• Ritonavir

• Patients unwilling or unable to attend the proposed visit schedule

• Patients suspected or known not to be trustworthy or who are likely not to comply with the study directives

Related Conditions & MeSH terms

• Bioavailability Study

Intervention

Drug:
• MP29-02
local nasal application
• Fluticasone propionate
local nasal application

Locations

Country	Name	City	State
Belgium	University Hospital Ghent, departement otorhinolaryngology	Ghent

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Ghent	MEDA Pharma GmbH & Co. KG, University of Wuerzburg

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	bioavailability of MP29-02 in human nasal mucosa compared to commercially available fluticasone propionate	bioavailability of both medicines will be tested in nasal mucosa and nasal secretion 1 after application	1 hour